-
1
-
-
65249145291
-
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection
-
Aldridge JR Jr, Moseley CE, Boltz DA et al (2009) TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 106:5306-5311
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 5306-5311
-
-
Aldridge, Jr.J.R.1
Moseley, C.E.2
Boltz, D.A.3
-
2
-
-
70349147840
-
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy
-
Alvarez R, Elbashir S, Borland T et al (2009) RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 53:3952-3962
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 3952-3962
-
-
Alvarez, R.1
Elbashir, S.2
Borland, T.3
-
3
-
-
0037259859
-
Early administration of oral oseltamivir increases the benefits of influenza treatment
-
Aoki FY, Macleod MD, Paggiaro P et al (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123-129
-
(2003)
J Antimicrob Chemother
, vol.51
, pp. 123-129
-
-
Aoki, F.Y.1
Macleod, M.D.2
Paggiaro, P.3
-
4
-
-
0023807899
-
Clinical pharmacokinetics of amantadine hydrochloride
-
Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14:35-51
-
(1988)
Clin Pharmacokinet
, vol.14
, pp. 35-51
-
-
Aoki, F.Y.1
Sitar, D.S.2
-
5
-
-
0017411851
-
Amantadine-resistance as a genetic marker for influenza viruses
-
Appleyard G (1977) Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol 36:249-255
-
(1977)
J Gen Virol
, vol.36
, pp. 249-255
-
-
Appleyard, G.1
-
6
-
-
0034699492
-
BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design
-
Babu YS, Chand P, Bantia S et al (2000) BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482-3486
-
(2000)
J Med Chem
, vol.43
, pp. 3482-3486
-
-
Babu, Y.S.1
Chand, P.2
Bantia, S.3
-
7
-
-
33846336137
-
Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005
-
Barr IG, Hurt AC, Iannello P et al (2007) Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Res 73:112-117
-
(2007)
Antiviral Res
, vol.73
, pp. 112-117
-
-
Barr, I.G.1
Hurt, A.C.2
Iannello, P.3
-
8
-
-
53249142257
-
Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries
-
Barr IG, Deng YM, Iannello P et al (2008) Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antiviral Res 80:200-205
-
(2008)
Antiviral Res
, vol.80
, pp. 200-205
-
-
Barr, I.G.1
Deng, Y.M.2
Iannello, P.3
-
9
-
-
0242586063
-
Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus
-
Barrientos LG, O'Keefe BR, Bray M et al (2003) Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res 58:47-56
-
(2003)
Antiviral Res
, vol.58
, pp. 47-56
-
-
Barrientos, L.G.1
O'Keefe, B.R.2
Bray, M.3
-
10
-
-
73349123478
-
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis
-
Baz M, Abed Y, Papenburg J et al (2009) Emergence of oseltamivir- resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 361:2296-2297
-
(2009)
N Engl J Med
, vol.361
, pp. 2296-2297
-
-
Baz, M.1
Abed, Y.2
Papenburg, J.3
-
11
-
-
38349068756
-
Update on avian influenza A (H5N1) virus infection in humans
-
bdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261-273
-
(2008)
N Engl J Med
, vol.358
, pp. 261-273
-
-
Bdel-Ghafar, A.N.1
Chotpitayasunondh, T.2
Gao, Z.3
-
12
-
-
77954071977
-
Treatment of severe cases of pandemic (H1N1) 2009 influenza: Reviewof antivirals and adjuvant therapy
-
Bearman GM, Shankaran S, Elam K (2010) Treatment of severe cases of pandemic (H1N1) 2009 influenza: reviewof antivirals and adjuvant therapy.Recent Pat Antiinfect Drug Discov 5:152-156
-
(2010)
Recent Pat Antiinfect Drug Discov
, vol.5
, pp. 152-156
-
-
Bearman, G.M.1
Shankaran, S.2
Elam, K.3
-
13
-
-
25444432780
-
Avian influenza A (H5N1) infection in humans
-
Beigel JH, Farrar J, Han AM et al (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374-1385
-
(2005)
N Engl J Med
, vol.353
, pp. 1374-1385
-
-
Beigel, J.H.1
Farrar, J.2
Han, A.M.3
-
14
-
-
38449093101
-
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection
-
Belser JA, Lu X, Szretter KJ et al (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196:1493-1499
-
(2007)
J Infect Dis
, vol.196
, pp. 1493-1499
-
-
Belser, J.A.1
Lu, X.2
Szretter, K.J.3
-
15
-
-
0023877609
-
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection
-
Belshe RB, Smith MH, Hall CB et al (1988) Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 62:1508-1512
-
(1988)
J Virol
, vol.62
, pp. 1508-1512
-
-
Belshe, R.B.1
Smith, M.H.2
Hall, C.B.3
-
16
-
-
11444260782
-
Influence of residue 44 on the activity of the M2 proton channel of influenza A virus
-
Betakova T, Ciampor F, Hay AJ (2005) Influence of residue 44 on the activity of the M2 proton channel of influenza A virus. J Gen Virol 86:181-184
-
(2005)
J Gen Virol
, vol.86
, pp. 181-184
-
-
Betakova, T.1
Ciampor, F.2
Hay, A.J.3
-
17
-
-
73349121665
-
The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza
-
Birnkrant D, Cox E (2009) The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 361:2204-2207
-
(2009)
N Engl J Med
, vol.361
, pp. 2204-2207
-
-
Birnkrant, D.1
Cox, E.2
-
18
-
-
0030790094
-
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
-
Boyd MR, Gustafson KR, McMahon JB et al (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41:1521-1530
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1521-1530
-
-
Boyd, M.R.1
Gustafson, K.R.2
McMahon, J.B.3
-
19
-
-
25844438380
-
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern
-
Bright RA, Medina MJ, Xu X et al (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 366:1175-1181
-
(2005)
Lancet
, vol.366
, pp. 1175-1181
-
-
Bright, R.A.1
Medina, M.J.2
Xu, X.3
-
20
-
-
33644536465
-
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States
-
Bright RA, Shay DK, Shu B et al (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894
-
(2006)
JAMA
, vol.295
, pp. 891-894
-
-
Bright, R.A.1
Shay, D.K.2
Shu, B.3
-
21
-
-
34547638447
-
Increased survival after gemfibrozil treatment of severe mouse influenza
-
Budd A, Alleva L, Alsharifi M et al (2007) Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 51:2965-2968
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 2965-2968
-
-
Budd, A.1
Alleva, L.2
Alsharifi, M.3
-
22
-
-
0032779292
-
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection
-
Calfee DP, Peng AW, Cass LM et al (1999) Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43:1616-1620
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1616-1620
-
-
Calfee, D.P.1
Peng, A.W.2
Cass, L.M.3
-
23
-
-
0036224388
-
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo
-
Carr J, Ives J, Kelly L et al (2002) Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 54:79-88
-
(2002)
Antiviral Res
, vol.54
, pp. 79-88
-
-
Carr, J.1
Ives, J.2
Kelly, L.3
-
24
-
-
0032996541
-
Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
-
Cass LM, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1):1-11
-
(1999)
Clin Pharmacokinet
, vol.36
, Issue.SUPPL. 1
, pp. 1-11
-
-
Cass, L.M.1
Efthymiopoulos, C.2
Bye, A.3
-
25
-
-
32544442997
-
High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season
-
Centers For Disease Control
-
Centers for Disease Control (2006) High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 55:44-46
-
(2006)
MMWR Morb Mortal Wkly Rep
, vol.55
, pp. 44-46
-
-
-
26
-
-
69249213677
-
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009
-
Centers For Disease Control
-
Centers for Disease Control (2009) Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58:893-896
-
(2009)
MMWR Morb Mortal Wkly Rep
, vol.58
, pp. 893-896
-
-
-
27
-
-
77950958001
-
Update: Influenza activity-United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine
-
Centers for Disease Control
-
Centers for Disease Control (2010) Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep 59:423-430
-
(2010)
MMWR Morb Mortal Wkly Rep
, vol.59
, pp. 423-430
-
-
-
28
-
-
37249013214
-
-
Accessed 8/4/10
-
Clinical Trials.gov (2010). http://www.ClinicalTrials.gov. Accessed 8/4/10
-
(2010)
Clinical Trials.Gov
-
-
-
29
-
-
0028113435
-
Influenza virus neuraminidase: Structure, antibodies, and inhibitors
-
Colman PM (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687-1696
-
(1994)
Protein Sci
, vol.3
, pp. 1687-1696
-
-
Colman, P.M.1
-
30
-
-
0027243201
-
Sequence and structure alignment of paramyxovirus hemagglutinin- neuraminidase with influenza virus neuraminidase
-
Colman PM, Hoyne PA, Lawrence MC (1993) Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 67: 2972-2980
-
(1993)
J Virol
, vol.67
, pp. 2972-2980
-
-
Colman, P.M.1
Hoyne, P.A.2
Lawrence, M.C.3
-
31
-
-
77649165379
-
Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs
-
Dapat C, Suzuki Y, Saito R et al (2010) Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 16:493-496
-
(2010)
Emerg Infect Dis
, vol.16
, pp. 493-496
-
-
Dapat, C.1
Suzuki, Y.2
Saito, R.3
-
32
-
-
0001055177
-
Antiviral activity of 1-adamantanamine (amantadine)
-
Davies WL, Grunert RR, Haff RF et al (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144:862-863
-
(1964)
Science
, vol.144
, pp. 862-863
-
-
Davies, W.L.1
Grunert, R.R.2
Haff, R.F.3
-
33
-
-
33751517736
-
Antiviral agents active against influenza A viruses
-
De Clerq E (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5:1015-1025
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 1015-1025
-
-
De Clerq, E.1
-
34
-
-
77952688315
-
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
-
DeVincenzo J, Lambkin-Williams R, Wilkinson T et al (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107:8800-8805
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 8800-8805
-
-
Devincenzo, J.1
Lambkin-Williams, R.2
Wilkinson, T.3
-
35
-
-
70449337979
-
Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008
-
Deyde V, Garten R, Sheu T et al (2009) Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respi Viruses 3:297-314
-
(2009)
Influenza Other Respi Viruses
, vol.3
, pp. 297-314
-
-
Deyde, V.1
Garten, R.2
Sheu, T.3
-
36
-
-
34447271704
-
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide
-
Deyde VM, Xu X, Bright RA et al (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249-257
-
(2007)
J Infect Dis
, vol.196
, pp. 249-257
-
-
Deyde, V.M.1
Xu, X.2
Bright, R.A.3
-
37
-
-
62149120632
-
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States
-
Dharan NJ, Gubareva LV, Meyer JJ et al (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041
-
(2009)
JAMA
, vol.301
, pp. 1034-1041
-
-
Dharan, N.J.1
Gubareva, L.V.2
Meyer, J.J.3
-
38
-
-
0019997609
-
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
-
Dolin R, Reichman RC, Madore HP et al (1982) A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 307:580-584
-
(1982)
N Engl J Med
, vol.307
, pp. 580-584
-
-
Dolin, R.1
Reichman, R.C.2
Madore, H.P.3
-
39
-
-
0031925539
-
Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus
-
Doyle WJ, Skoner DP, Alper CM et al (1998) Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 177:1260-1265
-
(1998)
J Infect Dis
, vol.177
, pp. 1260-1265
-
-
Doyle, W.J.1
Skoner, D.P.2
Alper, C.M.3
-
40
-
-
77957689934
-
Oseltamivir-resistant Pandemic H1N1 2009 influenza virus possesses lower transmissibility and fitness in ferrets
-
Duan S, Boltz DA, Seiler P et al (2010) Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 6:e1001022
-
(2010)
PLoS Pathog
, vol.6
-
-
Duan, S.1
Boltz, D.A.2
Seiler, P.3
-
41
-
-
77949656748
-
Safety and pharmacokinetics of oseltamivir at standard and high dosages
-
Dutkowski R, Smith JR, Davies BE (2010) Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents 35:461-467
-
(2010)
Int J Antimicrob Agents
, vol.35
, pp. 461-467
-
-
Dutkowski, R.1
Smith, J.R.2
Davies, B.E.3
-
42
-
-
84893045042
-
-
Endo Pharmaceuticals Inc (2007), Amantadine Package Insert
-
Endo Pharmaceuticals Inc (2007) Amantadine Package Insert. http://www.endo.com/PDF/symmetrel-pack-insert.pdf
-
-
-
-
43
-
-
77949653839
-
Treatment options for 2009 H1N1 influenza: Evaluation of the published evidence
-
Falagas ME, Vouloumanou EK, Baskouta E et al (2010) Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents 35:421-430
-
(2010)
Int J Antimicrob Agents
, vol.35
, pp. 421-430
-
-
Falagas, M.E.1
Vouloumanou, E.K.2
Baskouta, E.3
-
44
-
-
49349091075
-
Confronting an imminent pandemic with inexpensive generic agents: Can it be done?
-
Fedson DS (2008) Confronting an imminent pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 8:571-576
-
(2008)
Lancet Infect Dis
, vol.8
, pp. 571-576
-
-
Fedson, D.S.1
-
45
-
-
67649126476
-
Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: Why they are needed and how they might work
-
Fedson DS (2009) Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 3:129-142
-
(2009)
Influenza Other Respi Viruses
, vol.3
, pp. 129-142
-
-
Fedson, D.S.1
-
46
-
-
37349007892
-
Mutations of neuraminidase implicated in neuraminidase inhibitors resistance
-
Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41:13-19
-
(2008)
J Clin Virol
, vol.41
, pp. 13-19
-
-
Ferraris, O.1
Lina, B.2
-
47
-
-
77956636977
-
An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006
-
Fleming DM, Verlander NQ, Elliot AJ et al (2010) An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 138:1281-1288
-
(2010)
Epidemiol Infect
, vol.138
, pp. 1281-1288
-
-
Fleming, D.M.1
Verlander, N.Q.2
Elliot, A.J.3
-
48
-
-
84893105439
-
-
Forest Pharmaceuticals Inc (2010), Rimantadine Package Insert
-
Forest Pharmaceuticals Inc (2010) Rimantadine Package Insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/019649s015lbl.pdf
-
-
-
-
49
-
-
0036211719
-
In vitro and in vivo activities of anti-influenza virus compound T-705
-
Furuta Y, Takahashi K, Fukuda Y et al (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 977-981
-
-
Furuta, Y.1
Takahashi, K.2
Fukuda, Y.3
-
51
-
-
64749093901
-
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
-
Furuta Y, Takahashi K, Shiraki K et al (2009) T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102
-
(2009)
Antiviral Res
, vol.82
, pp. 95-102
-
-
Furuta, Y.1
Takahashi, K.2
Shiraki, K.3
-
52
-
-
33845462128
-
Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice
-
Galabov AS, Simeonova L, Gegova G (2006) Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 17:251-258
-
(2006)
Antivir Chem Chemother
, vol.17
, pp. 251-258
-
-
Galabov, A.S.1
Simeonova, L.2
Gegova, G.3
-
53
-
-
70450221927
-
N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus
-
Geiler J, Michaelis M, Naczk P et al (2010) N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 79:413-420
-
(2010)
Biochem Pharmacol
, vol.79
, pp. 413-420
-
-
Geiler, J.1
Michaelis, M.2
Naczk, P.3
-
54
-
-
0022619527
-
Studies on the mechanism of membrane fusion: Sitespecific mutagenesis of the hemagglutinin of influenza virus
-
Gething MJ, Doms RW, York D et al (1986) Studies on the mechanism of membrane fusion: sitespecific mutagenesis of the hemagglutinin of influenza virus. J Cell Biol 102:11-23
-
(1986)
J Cell Biol
, vol.102
, pp. 11-23
-
-
Gething, M.J.1
Doms, R.W.2
York, D.3
-
55
-
-
9644262504
-
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells
-
Govorkova EA, Fang HB, Tan M et al (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48:4855-4863
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 4855-4863
-
-
Govorkova, E.A.1
Fang, H.B.2
Tan, M.3
-
56
-
-
79251559935
-
Combination chemotherapy for influenza
-
Govorkova EA, Webster RG (2010) Combination chemotherapy for influenza. Viruses 2:1510-1529
-
(2010)
Viruses
, vol.2
, pp. 1510-1529
-
-
Govorkova, E.A.1
Webster, R.G.2
-
57
-
-
0027103930
-
Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses
-
Grambas S, Bennett MS, Hay AJ (1992) Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 191:541-549
-
(1992)
Virology
, vol.191
, pp. 541-549
-
-
Grambas, S.1
Bennett, M.S.2
Hay, A.J.3
-
58
-
-
0031000886
-
Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
-
Gubareva LV, Robinson MJ, Bethell RC et al (1997) Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71:3385-3390
-
(1997)
J Virol
, vol.71
, pp. 3385-3390
-
-
Gubareva, L.V.1
Robinson, M.J.2
Bethell, R.C.3
-
59
-
-
0034603350
-
Influenza virus neuraminidase inhibitors
-
Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355:827-835
-
(2000)
Lancet
, vol.355
, pp. 827-835
-
-
Gubareva, L.V.1
Kaiser, L.2
Hayden, F.G.3
-
60
-
-
77949589032
-
First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales
-
Gulland A (2009) First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales. BMJ 339:b4975
-
(2009)
BMJ
, vol.339
-
-
Gulland, A.1
-
61
-
-
39049101312
-
Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children
-
Gums JG, Pelletier EM, Blumentals WA (2008) Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother 9:151-161
-
(2008)
Expert Opin Pharmacother
, vol.9
, pp. 151-161
-
-
Gums, J.G.1
Pelletier, E.M.2
Blumentals, W.A.3
-
62
-
-
63649087759
-
Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical practice guidelines of the Infectious Diseases Society of America
-
Harper SA, Bradley JS, Englund JA et al (2009) Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48:1003-1032
-
(2009)
Clin Infect Dis
, vol.48
, pp. 1003-1032
-
-
Harper, S.A.1
Bradley, J.S.2
Englund, J.A.3
-
63
-
-
77950995999
-
Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus
-
Harter G, Zimmermann O, Maier L et al (2010) Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 50:1249-1251
-
(2010)
Clin Infect Dis
, vol.50
, pp. 1249-1251
-
-
Harter, G.1
Zimmermann, O.2
Maier, L.3
-
64
-
-
0022976956
-
Molecular basis of resistance of influenza A viruses to amantadine
-
Hay AJ, Zambon MC, Wolstenholme AJ et al (1986) Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 18(Suppl B):19-29
-
(1986)
J Antimicrob Chemother
, vol.18
, Issue.SUPPL.B
, pp. 19-29
-
-
Hay, A.J.1
Zambon, M.C.2
Wolstenholme, A.J.3
-
65
-
-
0021352019
-
Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro
-
Hayden FG, Schlepushkin AN, Pushkarskaya NL (1984) Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 25:53-57
-
(1984)
Antimicrob Agents Chemother
, vol.25
, pp. 53-57
-
-
Hayden, F.G.1
Schlepushkin, A.N.2
Pushkarskaya, N.L.3
-
66
-
-
0022612664
-
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
-
Hayden FG, Monto AS (1986) Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 29:339-341
-
(1986)
Antimicrob Agents Chemother
, vol.29
, pp. 339-341
-
-
Hayden, F.G.1
Monto, A.S.2
-
67
-
-
0001971311
-
Amantidine and rimantidine-clinical aspects
-
In: Richman DD (ed)
-
Hayden FG (1996) Amantidine and rimantidine-clinical aspects. In: Richman DD (ed) Antiviral Drug Resistance, Wiley, pp. 59-77
-
(1996)
Antiviral Drug Resistance Wiley
, pp. 59-77
-
-
Hayden, F.G.1
-
68
-
-
9844220300
-
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections
-
GG167 Influenza Study Group
-
Hayden FG, Osterhaus AD, Treanor JJ et al (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337:874-880
-
(1997)
N Engl J Med
, vol.337
, pp. 874-880
-
-
Hayden, F.G.1
Osterhaus, A.D.2
Treanor, J.J.3
-
69
-
-
0032696188
-
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
-
Hayden FG, Atmar RL, Schilling M et al (1999a) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336-1343
-
(1999)
N Engl J Med
, vol.341
, pp. 1336-1343
-
-
Hayden, F.G.1
Atmar, R.L.2
Schilling, M.3
-
70
-
-
0033530264
-
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
-
Hayden FG, Treanor JJ, Fritz RS et al (1999b) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246
-
(1999)
JAMA
, vol.282
, pp. 1240-1246
-
-
Hayden, F.G.1
Treanor, J.J.2
Fritz, R.S.3
-
71
-
-
0034597724
-
Inhaled zanamivir for the prevention of influenza in families
-
Zanamivir Family Study Group
-
Hayden FG, Gubareva LV, Monto AS et al (2000) Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 343:1282-1289
-
(2000)
N Engl J Med
, vol.343
, pp. 1282-1289
-
-
Hayden, F.G.1
Gubareva, L.V.2
Monto, A.S.3
-
72
-
-
1142309473
-
Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis
-
Hayden FG, Belshe R, Villanueva C et al (2004) Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189:440-449
-
(2004)
J Infect Dis
, vol.189
, pp. 440-449
-
-
Hayden, F.G.1
Belshe, R.2
Villanueva, C.3
-
73
-
-
33344475829
-
Antiviral resistance in influenza viruses - Implications for management and pandemic response
-
Hayden FG (2006) Antiviral resistance in influenza viruses - implications for management and pandemic response. N Engl J Med 354:785-788
-
(2006)
N Engl J Med
, vol.354
, pp. 785-788
-
-
Hayden, F.G.1
-
74
-
-
57749187455
-
Developing new antiviral agents for influenza treatment: What does the future hold?
-
Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48(Suppl 1):S3-S13
-
(2009)
Clin Infect Dis
, vol.48
, Issue.SUPPL. 1
-
-
Hayden, F.1
-
75
-
-
0033385681
-
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802
-
He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484
-
(1999)
Clin Pharmacokinet
, vol.37
, pp. 471-484
-
-
He, G.1
Massarella, J.2
Ward, P.3
-
76
-
-
0036228067
-
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
-
Herlocher ML, Carr J, Ives J et al (2002) Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 54:99-111
-
(2002)
Antiviral Res
, vol.54
, pp. 99-111
-
-
Herlocher, M.L.1
Carr, J.2
Ives, J.3
-
77
-
-
6944227719
-
Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets
-
Herlocher ML, Truscon R, Elias S et al (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190:1627-1630
-
(2004)
J Infect Dis
, vol.190
, pp. 1627-1630
-
-
Herlocher, M.L.1
Truscon, R.2
Elias, S.3
-
78
-
-
65149099661
-
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en
-
Honda T, Kubo S, Masuda T et al (2009) Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg Med Chem Lett 19:2938-2940
-
(2009)
Bioorg Med Chem Lett
, vol.19
, pp. 2938-2940
-
-
Honda, T.1
Kubo, S.2
Masuda, T.3
-
79
-
-
77955359911
-
Treatment of hepatitis C in children: A systematic review
-
Hu J, Doucette K, Hartling L et al (2010) Treatment of hepatitis C in children: A systematic review. PLoS ONE 5:e11542
-
(2010)
PLoS ONE
, vol.5
-
-
Hu, J.1
Doucette, K.2
Hartling, L.3
-
80
-
-
70349728568
-
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation
-
Hurt AC, Holien JK, Parker M et al (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83:10366-10373
-
(2009)
J Virol
, vol.83
, pp. 10366-10373
-
-
Hurt, A.C.1
Holien, J.K.2
Parker, M.3
-
81
-
-
34249001427
-
Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice
-
Ilyushina NA, Hoffmann E, Salomon R et al (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12:363-370
-
(2007)
Antivir Ther
, vol.12
, pp. 363-370
-
-
Ilyushina, N.A.1
Hoffmann, E.2
Salomon, R.3
-
82
-
-
55849102109
-
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice
-
Ilyushina NA, Hay A, Yilmaz N et al (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.AntimicrobAgents Chemother 52:3889-3897
-
(2008)
AntimicrobAgents Chemother
, vol.52
, pp. 3889-3897
-
-
Ilyushina, N.A.1
Hay, A.2
Yilmaz, N.3
-
83
-
-
77955448761
-
Clinical pharmacokinetics of Laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of Its prodrug, CS-8958, in Healthy Male Volunteers
-
Ishizuka H, Yoshiba S, Okabe H et al (2010) Clinical pharmacokinetics of Laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of Its prodrug, CS-8958, in Healthy Male Volunteers. J Clin Pharmacol 50:1319-1329
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 1319-1329
-
-
Ishizuka, H.1
Yoshiba, S.2
Okabe, H.3
-
84
-
-
0042656406
-
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza
-
Ison MG, Gnann JW Jr, Nagy-Agren S et al (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8:183-190
-
(2003)
Antivir Ther
, vol.8
, pp. 183-190
-
-
Ison, M.G.1
Gnann, Jr.J.W.2
Nagy-Agren, S.3
-
85
-
-
69149093400
-
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
-
Itoh Y, Shinya K, Kiso M et al (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025
-
(2009)
Nature
, vol.460
, pp. 1021-1025
-
-
Itoh, Y.1
Shinya, K.2
Kiso, M.3
-
86
-
-
0036294323
-
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
-
Ives JA, Carr JA, Mendel DB et al (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55:307-317
-
(2002)
Antiviral Res
, vol.55
, pp. 307-317
-
-
Ives, J.A.1
Carr, J.A.2
Mendel, D.B.3
-
87
-
-
77950960240
-
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
-
Jefferson T, Jones M, Doshi P et al (2010) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2:CD001265
-
(2010)
Cochrane Database Syst Rev
, vol.2
-
-
Jefferson, T.1
Jones, M.2
Doshi, P.3
-
88
-
-
0042259159
-
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations
-
Kaiser L, Wat C, Mills T et al (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667-1672
-
(2003)
Arch Intern Med
, vol.163
, pp. 1667-1672
-
-
Kaiser, L.1
Wat, C.2
Mills, T.3
-
89
-
-
77957678820
-
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries
-
Kashyap AK, Steel J, Rubrum A et al (2010) Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 6:e1000990
-
(2010)
PLoS Pathog
, vol.6
-
-
Kashyap, A.K.1
Steel, J.2
Rubrum, A.3
-
90
-
-
37149003148
-
A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B
-
Kawai N, Ikematsu H, Iwaki N et al (2008) A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 56:51-57
-
(2008)
J Infect
, vol.56
, pp. 51-57
-
-
Kawai, N.1
Ikematsu, H.2
Iwaki, N.3
-
91
-
-
0031048319
-
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
-
Kim CU, Lew W, Williams MA et al (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681-690
-
(1997)
J Am Chem Soc
, vol.119
, pp. 681-690
-
-
Kim, C.U.1
Lew, W.2
Williams, M.A.3
-
92
-
-
77649196693
-
Safety of oseltamivir compared with the adamantanes in children less than 12 months of age
-
Kimberlin DW, Shalabi M, Abzug MJ et al (2010) Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 29:195-198
-
(2010)
Pediatr Infect Dis J
, vol.29
, pp. 195-198
-
-
Kimberlin, D.W.1
Shalabi, M.2
Abzug, M.J.3
-
93
-
-
4444369826
-
Resistant influenza A viruses in children treated with oseltamivir: Descriptive study
-
Kiso M, Mitamura K, Sakai-Tagawa Y et al (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765
-
(2004)
Lancet
, vol.364
, pp. 759-765
-
-
Kiso, M.1
Mitamura, K.2
Sakai-Tagawa, Y.3
-
94
-
-
77649254587
-
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses
-
Kiso M, Kubo S, Ozawa M et al (2010a) Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6:e1000786
-
(2010)
PLoS Pathog
, vol.6
-
-
Kiso, M.1
Kubo, S.2
Ozawa, M.3
-
95
-
-
76249125006
-
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
-
Kiso M, Takahashi K, Sakai-Tagawa Y et al (2010b) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107:882-887
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 882-887
-
-
Kiso, M.1
Takahashi, K.2
Sakai-Tagawa, Y.3
-
96
-
-
33845609269
-
Successful treatment of avian influenza with convalescent plasma
-
Kong LK, Zhou BP (2006) Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 12:489
-
(2006)
Hong Kong Med J
, vol.12
, pp. 489
-
-
Kong, L.K.1
Zhou, B.P.2
-
97
-
-
70350328007
-
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract
-
Koyama K, Takahashi M, Oitate M et al (2009) CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 53:4845-4851
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 4845-4851
-
-
Koyama, K.1
Takahashi, M.2
Oitate, M.3
-
98
-
-
77649151800
-
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses
-
Krause JC, Tumpey TM, Huffman CJ et al (2010) Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 84:3127-3130
-
(2010)
J Virol
, vol.84
, pp. 3127-3130
-
-
Krause, J.C.1
Tumpey, T.M.2
Huffman, C.J.3
-
99
-
-
77149156604
-
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration
-
Kubo S, Tomozawa T, Kakuta M et al (2010) Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 54:1256-1264
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 1256-1264
-
-
Kubo, S.1
Tomozawa, T.2
Kakuta, M.3
-
100
-
-
70449653474
-
Critically ill patients with 2009 influenza A(H1N1) infection in Canada
-
Kumar A, Zarychanski R, Pinto R et al (2009) Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302:1872-1879
-
(2009)
JAMA
, vol.302
, pp. 1872-1879
-
-
Kumar, A.1
Zarychanski, R.2
Pinto, R.3
-
101
-
-
77954959944
-
Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs
-
Kumar P, Sood V, Vyas R et al (2010) Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs. Antiviral Res 87:204-212
-
(2010)
Antiviral Res
, vol.87
, pp. 204-212
-
-
Kumar, P.1
Sood, V.2
Vyas, R.3
-
102
-
-
40549111715
-
HIV-1: Pathogenesis, clinical manifestations, and treatment
-
In: Knipe DM, Howley PM (eds), Fifth, 5th edn., Lippincott Williams and Wilkins, Philadelphia
-
Kuritzkes DR, Walker BD (2007) HIV-1: pathogenesis, clinical manifestations, and treatment. In: Knipe DM, Howley PM (eds) Fields virology, Fifth, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1697-1701
-
(2007)
Fields Virology
, pp. 1697-1701
-
-
Kuritzkes, D.R.1
Walker, B.D.2
-
103
-
-
77951216706
-
Influenza morbidity and mortality in elderly patients receiving statins: A cohort study
-
Kwong JC, Li P, Redelmeier DA (2009) Influenza morbidity and mortality in elderly patients receiving statins: A cohort study. PLoS ONE 4:e8087
-
(2009)
PLoS ONE
, vol.4
-
-
Kwong, J.C.1
Li, P.2
Redelmeier, D.A.3
-
104
-
-
40549111528
-
Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe
-
Lackenby A, Hungnes O, Dudman SG et al (2008) Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 13:8026
-
(2008)
Euro Surveill
, vol.13
, pp. 8026
-
-
Lackenby, A.1
Hungnes, O.2
Dudman, S.G.3
-
105
-
-
27144468290
-
Avian flu: Isolation of drug-resistant H5N1 virus
-
Le QM, Kiso M, Someya K et al (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108
-
(2005)
Nature
, vol.437
, pp. 1108
-
-
Le, Q.M.1
Kiso, M.2
Someya, K.3
-
106
-
-
74949097490
-
A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza
-
Le QM, Wertheim HF, Tran ND et al (2010) A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362:86-87
-
(2010)
N Engl J Med
, vol.362
, pp. 86-87
-
-
Le, Q.M.1
Wertheim, H.F.2
Tran, N.D.3
-
107
-
-
0033651178
-
The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
-
Leneva IA, Roberts N, Govorkova EA et al (2000) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101-115
-
(2000)
Antiviral Res
, vol.48
, pp. 101-115
-
-
Leneva, I.A.1
Roberts, N.2
Govorkova, E.A.3
-
108
-
-
72049092943
-
Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong
-
Leung TW, Tai AL, Cheng PK et al (2009) Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 46:298-299
-
(2009)
J Clin Virol
, vol.46
, pp. 298-299
-
-
Leung, T.W.1
Tai, A.L.2
Cheng, P.K.3
-
109
-
-
70349122084
-
Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice
-
Liu Z, Guo Z, Wang G et al (2009) Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 38:215-223
-
(2009)
Eur J Pharm Sci
, vol.38
, pp. 215-223
-
-
Liu, Z.1
Guo, Z.2
Wang, G.3
-
110
-
-
77950219752
-
Hark back: Passive immunotherapy for influenza and other serious infections
-
Luke TC, Casadevall A, Watowich SJ et al (2010) Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66-e73
-
(2010)
Crit Care Med
, vol.38
-
-
Luke, T.C.1
Casadevall, A.2
Watowich, S.J.3
-
111
-
-
33750721332
-
Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?
-
Luke TC, Kilbane EM, Jackson JL et al (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 145:599-609
-
(2006)
Ann Intern Med
, vol.145
, pp. 599-609
-
-
Luke, T.C.1
Kilbane, E.M.2
Jackson, J.L.3
-
112
-
-
33645765519
-
Sialidase fusion protein as a novel broadspectrum inhibitor of influenza virus infection
-
Malakhov MP, Aschenbrenner LM, Smee DF et al (2006) Sialidase fusion protein as a novel broadspectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 50:1470-1479
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 1470-1479
-
-
Malakhov, M.P.1
Aschenbrenner, L.M.2
Smee, D.F.3
-
113
-
-
77951912211
-
Evaluation of the efficacy of a specific hyperimmune serum in experimental influenza infection in mice
-
Marinescu B, Coman C, Iancu AD et al (2009) Evaluation of the efficacy of a specific hyperimmune serum in experimental influenza infection in mice. Roum Arch Microbiol Immunol 68:80-82
-
(2009)
Roum Arch Microbiol Immunol
, vol.68
, pp. 80-82
-
-
Marinescu, B.1
Coman, C.2
Iancu, A.D.3
-
114
-
-
60849088256
-
Neutralizing anti-influenza virus monoclonal antibodies: Therapeutics and tools for discovery
-
Martinez O, Tsibane T, Basler CF (2009) Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol 28:69-92
-
(2009)
Int Rev Immunol
, vol.28
, pp. 69-92
-
-
Martinez, O.1
Tsibane, T.2
Basler, C.F.3
-
115
-
-
0037770271
-
Overexpression of the alpha-2,6- sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors
-
Matrosovich M, Matrosovich T, Carr J et al (2003) Overexpression of the alpha-2,6- sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77:8418-8425
-
(2003)
J Virol
, vol.77
, pp. 8418-8425
-
-
Matrosovich, M.1
Matrosovich, T.2
Carr, J.3
-
116
-
-
7644241814
-
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium
-
Matrosovich MN, Matrosovich TY, Gray T et al (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665-12667
-
(2004)
J Virol
, vol.78
, pp. 12665-12667
-
-
Matrosovich, M.N.1
Matrosovich, T.Y.2
Gray, T.3
-
117
-
-
0035096415
-
Oseltamivir: A review of its use in influenza
-
McClellan K, Perry CM (2001) Oseltamivir: A review of its use in influenza. Drugs 61:263-283
-
(2001)
Drugs
, vol.61
, pp. 263-283
-
-
McClellan, K.1
Perry, C.M.2
-
118
-
-
3242812828
-
Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza
-
McCullers JA (2004) Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190:519-526
-
(2004)
J Infect Dis
, vol.190
, pp. 519-526
-
-
McCullers, J.A.1
-
120
-
-
56149096005
-
Preparing for the next influenza pandemic
-
McCullers JA (2008) Preparing for the next influenza pandemic. Pediatr Infect Dis J 27:S57-S59
-
(2008)
Pediatr Infect Dis J
, vol.27
-
-
McCullers, J.A.1
-
121
-
-
0033897803
-
Resistance of influenza viruses to neuraminidase inhibitors-A review
-
McKimm-Breschkin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 47:1-17
-
(2000)
Antiviral Res
, vol.47
, pp. 1-17
-
-
McKimm-Breschkin, J.L.1
-
122
-
-
0036166775
-
Neuraminidase inhibitors for the treatment and prevention of influenza
-
McKimm-Breschkin JL (2002) Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother 3:103-112
-
(2002)
Expert Opin Pharmacother
, vol.3
, pp. 103-112
-
-
McKimm-Breschkin, J.L.1
-
123
-
-
77950996301
-
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts
-
Memoli MJ, Hrabal RJ, Hassantoufighi A et al (2010) Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 50:1252-1255
-
(2010)
Clin Infect Dis
, vol.50
, pp. 1252-1255
-
-
Memoli, M.J.1
Hrabal, R.J.2
Hassantoufighi, A.3
-
124
-
-
0018396775
-
Prevention of Russian influenza by amantadine
-
Monto AS, Gunn RA, Bandyk MG et al (1979) Prevention of Russian influenza by amantadine. JAMA 241:1003-1007
-
(1979)
JAMA
, vol.241
, pp. 1003-1007
-
-
Monto, A.S.1
Gunn, R.A.2
Bandyk, M.G.3
-
125
-
-
0033532975
-
Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
-
Monto AS, Robinson DP, Herlocher ML et al (1999) Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA 282:31-35
-
(1999)
JAMA
, vol.282
, pp. 31-35
-
-
Monto, A.S.1
Robinson, D.P.2
Herlocher, M.L.3
-
126
-
-
44949100462
-
A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination
-
Morrison D, Roy S, Rayner C et al (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2:e1305
-
(2007)
PLoS ONE
, vol.2
-
-
Morrison, D.1
Roy, S.2
Rayner, C.3
-
127
-
-
61849118968
-
Global transmission of oseltamivir-resistant influenza
-
MosconaA(2009) Global transmission of oseltamivir-resistant influenza.NEngl JMed 360:953-956
-
(2009)
NEngl JMed
, vol.360
, pp. 953-956
-
-
Moscona, A.1
-
128
-
-
77954573573
-
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo
-
Moscona A, Porotto M, Palmer S et al (2010) A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 202:234-241
-
(2010)
J Infect Dis
, vol.202
, pp. 234-241
-
-
Moscona, A.1
Porotto, M.2
Palmer, S.3
-
129
-
-
77953517101
-
Targeting pandemic influenza: A primer on influenza antivirals and drug resistance
-
Moss RB, Davey RT, Steigbigel RT et al (2010) Targeting pandemic influenza: A primer on influenza antivirals and drug resistance. J Antimicrob Chemother 65:1086-1093
-
(2010)
J Antimicrob Chemother
, vol.65
, pp. 1086-1093
-
-
Moss, R.B.1
Davey, R.T.2
Steigbigel, R.T.3
-
130
-
-
77950274542
-
Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure
-
Napolitano LM, Park PK, Raghavendran K et al (2010) Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med 38:e74-e90
-
(2010)
Crit Care Med
, vol.38
-
-
Napolitano, L.M.1
Park, P.K.2
Raghavendran, K.3
-
131
-
-
67349177735
-
The origin and global emergence of adamantane resistant A/H3N2 influenza viruses
-
Nelson MI, Simonsen L, Viboud C et al (2009) The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388:270-278
-
(2009)
Virology
, vol.388
, pp. 270-278
-
-
Nelson, M.I.1
Simonsen, L.2
Viboud, C.3
-
132
-
-
77949639846
-
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro
-
Nguyen JT, Hoopes JD, Le MH et al (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 5:e9332
-
(2010)
PLoS ONE
, vol.5
-
-
Nguyen, J.T.1
Hoopes, J.D.2
Le, M.H.3
-
133
-
-
70349331605
-
Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro
-
Nguyen JT, Hoopes JD, Smee DF et al (2009) Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53:4115-4126
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 4115-4126
-
-
Nguyen, J.T.1
Hoopes, J.D.2
Smee, D.F.3
-
134
-
-
0034720503
-
Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial
-
Neuraminidase Inhibitor Flu Treatment Investigator Group
-
Nicholson KG, Aoki FY, Osterhaus AD et al (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845-1850
-
(2000)
Lancet
, vol.355
, pp. 1845-1850
-
-
Nicholson, K.G.1
Aoki, F.Y.2
Osterhaus, A.D.3
-
135
-
-
68149183702
-
Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan
-
Nishiura H, Castillo-Chavez C, Safan M et al (2009) Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan. Euro Surveill 14
-
(2009)
Euro Surveill
, vol.14
-
-
Nishiura, H.1
Castillo-Chavez, C.2
Safan, M.3
-
136
-
-
0043270574
-
Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin
-
O'Keefe BR, Smee DF, Turpin JA et al (2003) Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 47:2518-2525
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 2518-2525
-
-
O'Keefe, B.R.1
Smee, D.F.2
Turpin, J.A.3
-
137
-
-
36248992909
-
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes
-
Orzeck EA, Shi N, Blumentals WA (2007) Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther 29:2246-2255
-
(2007)
Clin Ther
, vol.29
, pp. 2246-2255
-
-
Orzeck, E.A.1
Shi, N.2
Blumentals, W.A.3
-
138
-
-
68149107226
-
Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico
-
Perez-Padilla R, de la Rosa-Zamboni Ponce, de Leon S et al (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361:680-689
-
(2009)
N Engl J Med
, vol.361
, pp. 680-689
-
-
Perez-Padilla, R.1
De La Rosa-Zamboni Ponce2
De Leon, S.3
-
139
-
-
67649611236
-
Effects of oseltamivir on influenza-related complications in children with chronic medical conditions
-
Piedra PA, Schulman KL, Blumentals WA (2009) Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 124:170-178
-
(2009)
Pediatrics
, vol.124
, pp. 170-178
-
-
Piedra, P.A.1
Schulman, K.L.2
Blumentals, W.A.3
-
140
-
-
0026612385
-
Influenza virus M2 protein has ion channel activity
-
Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69:517-528
-
(1992)
Cell
, vol.69
, pp. 517-528
-
-
Pinto, L.H.1
Holsinger, L.J.2
Lamb, R.A.3
-
141
-
-
0036262198
-
Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy
-
Raboud JM, Harris M, Rae S et al (2002) Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 3:118-124
-
(2002)
HIV Med
, vol.3
, pp. 118-124
-
-
Raboud, J.M.1
Harris, M.2
Rae, S.3
-
142
-
-
0031948292
-
Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments
-
Ramisse F, Deramoudt FX, Szatanik M et al (1998) Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol 111:583-587
-
(1998)
Clin Exp Immunol
, vol.111
, pp. 583-587
-
-
Ramisse, F.1
Deramoudt, F.X.2
Szatanik, M.3
-
143
-
-
77149123171
-
Does glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza?
-
Reichert T, Chowell G, Nishiura H et al (2010) Does glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis 10:5
-
(2010)
BMC Infect Dis
, vol.10
, pp. 5
-
-
Reichert, T.1
Chowell, G.2
Nishiura, H.3
-
144
-
-
0037560121
-
High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza
-
Shiraishi K, Mitamura K, Sakai-TagawaYet al (2003) High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188:57-61
-
(2003)
J Infect Dis
, vol.188
, pp. 57-61
-
-
Shiraishi, K.1
Mitamura, K.2
Sakai-Tagawa, Y.3
-
145
-
-
25144433955
-
In vitro and in vivo influenza virus-inhibitory effects of viramidine
-
Sidwell RW, Bailey KW, Wong MH et al (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 68:10-17
-
(2005)
Antiviral Res
, vol.68
, pp. 10-17
-
-
Sidwell, R.W.1
Bailey, K.W.2
Wong, M.H.3
-
146
-
-
33847688459
-
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice
-
Sidwell RW, Barnard DL, Day CW et al (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845-851
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 845-851
-
-
Sidwell, R.W.1
Barnard, D.L.2
Day, C.W.3
-
147
-
-
77952645453
-
In Vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses
-
Sleeman K, Mishin VP, Deyde VM et al (2010) In Vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54:2517-2524
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 2517-2524
-
-
Sleeman, K.1
Mishin, V.P.2
Deyde, V.M.3
-
148
-
-
0036244498
-
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ- 270201 and ribavirin
-
Smee DF, Bailey KW, Morrison AC et al (2002) Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ- 270201 and ribavirin. Chemotherapy 48:88-93
-
(2002)
Chemotherapy
, vol.48
, pp. 88-93
-
-
Smee, D.F.1
Bailey, K.W.2
Morrison, A.C.3
-
149
-
-
56349088765
-
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N
-
Smee DF, Bailey KW, Wong MH et al (2008) Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 80:266-271
-
(2008)
Antiviral Res
, vol.80
, pp. 266-271
-
-
Smee, D.F.1
Bailey, K.W.2
Wong, M.H.3
-
150
-
-
73849083795
-
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice
-
Smee DF, Hurst BL, Wong MH et al (2010) Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54:126-133
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 126-133
-
-
Smee, D.F.1
Hurst, B.L.2
Wong, M.H.3
-
151
-
-
41349092581
-
Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor
-
Smee DF, Wandersee MK, Checketts MB et al (2007) Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor. Antivir Chem Chemother 18:317-327
-
(2007)
Antivir Chem Chemother
, vol.18
, pp. 317-327
-
-
Smee, D.F.1
Wandersee, M.K.2
Checketts, M.B.3
-
152
-
-
33947105014
-
Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
-
Smee DF, Wong MH, Bailey KW et al (2006) Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 17:185-192
-
(2006)
Antivir Chem Chemother
, vol.17
, pp. 185-192
-
-
Smee, D.F.1
Wong, M.H.2
Bailey, K.W.3
-
153
-
-
0029560199
-
Molecular basis for the resistance of influenza viruses to 4- guanidino-Neu5Ac2en
-
Staschke KA, Colacino JM, Baxter AJ et al (1995) Molecular basis for the resistance of influenza viruses to 4- guanidino-Neu5Ac2en. Virology 214:642-646
-
(1995)
Virology
, vol.214
, pp. 642-646
-
-
Staschke, K.A.1
Colacino, J.M.2
Baxter, A.J.3
-
155
-
-
33645865234
-
Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome
-
Steinberg KP, Hudson LD, Goodman RB et al (2006) Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671-1684
-
(2006)
N Engl J Med
, vol.354
, pp. 1671-1684
-
-
Steinberg, K.P.1
Hudson, L.D.2
Goodman, R.B.3
-
156
-
-
0029828938
-
Studies using double mutants of the conformational transitions in influenza hemagglutinin required for its membrane fusion activity
-
Steinhauer DA, Martin J, Lin YP et al (1996) Studies using double mutants of the conformational transitions in influenza hemagglutinin required for its membrane fusion activity. Proc Natl Acad Sci USA 93:12873-12878
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 12873-12878
-
-
Steinhauer, D.A.1
Martin, J.2
Lin, Y.P.3
-
158
-
-
0036171882
-
Influenza B infection associated with encephalitis: Treatment with oseltamivir
-
Straumanis JP, Tapia MD, King JC (2002) Influenza B infection associated with encephalitis: treatment with oseltamivir. Pediatr Infect Dis J 21:173-175
-
(2002)
Pediatr Infect Dis J
, vol.21
, pp. 173-175
-
-
Straumanis, J.P.1
Tapia, M.D.2
King, J.C.3
-
159
-
-
77952611625
-
Long-acting neuraminidase inhibitor laninamivir octanoate (CS- 8958) versus oseltamivir as treatment for children with influenza virus infection
-
Sugaya N, Ohashi Y (2010) Long-acting neuraminidase inhibitor laninamivir octanoate (CS- 8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54:2575-2582
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 2575-2582
-
-
Sugaya, N.1
Ohashi, Y.2
-
160
-
-
0031787185
-
Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
-
Tai CY, Escarpe PA, Sidwell RW et al (1998) Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:3234-3241
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 3234-3241
-
-
Tai, C.Y.1
Escarpe, P.A.2
Sidwell, R.W.3
-
161
-
-
0344236356
-
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus
-
Takahashi K, Furuta Y, Fukuda Y et al (2003) In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 14:235-241
-
(2003)
Antivir Chem Chemother
, vol.14
, pp. 235-241
-
-
Takahashi, K.1
Furuta, Y.2
Fukuda, Y.3
-
162
-
-
17744412173
-
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial
-
US Oral Neuraminidase Study Group
-
Treanor JJ, Hayden FG, Vrooman PS et al (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283:1016-1024
-
(2000)
JAMA
, vol.283
, pp. 1016-1024
-
-
Treanor, J.J.1
Hayden, F.G.2
Vrooman, P.S.3
-
163
-
-
70450198610
-
Inhibition of neuraminidase inhibitorresistant influenza virus by DAS181, a novel sialidase fusion protein
-
Triana-Baltzer GB, Gubareva LV, Klimov AI et al (2009a) Inhibition of neuraminidase inhibitorresistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 4:e7838
-
(2009)
PLoS ONE
, vol.4
-
-
Triana-Baltzer, G.B.1
Gubareva, L.V.2
Klimov, A.I.3
-
164
-
-
70450175741
-
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein
-
Triana-Baltzer GB, Gubareva LV, Nicholls JM et al (2009b) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4:e7788
-
(2009)
PLoS ONE
, vol.4
-
-
Triana-Baltzer, G.B.1
Gubareva, L.V.2
Nicholls, J.M.3
-
165
-
-
0019516791
-
Successful treatment of naturally occurring influenza A/USSR/77 H1N1
-
Van Voris LP, Betts RF, Hayden FG et al (1981) Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 245:1128-1131
-
(1981)
JAMA
, vol.245
, pp. 1128-1131
-
-
Van Voris, L.P.1
Betts, R.F.2
Hayden, F.G.3
-
166
-
-
0030044141
-
A study of the active site of influenza virus sialidase: An approach to the rational design of novel anti-influenza drugs
-
von Itzstein M, Dyason JC, Oliver SW et al (1996) A study of the active site of influenza virus sialidase: An approach to the rational design of novel anti-influenza drugs. J Med Chem 39:388-391
-
(1996)
J Med Chem
, vol.39
, pp. 388-391
-
-
Von Itzstein, M.1
Dyason, J.C.2
Oliver, S.W.3
-
167
-
-
0027185716
-
Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block
-
Wang C, Takeuchi K, Pinto LH et al (1993) Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 67:5585-5594
-
(1993)
J Virol
, vol.67
, pp. 5585-5594
-
-
Wang, C.1
Takeuchi, K.2
Pinto, L.H.3
-
168
-
-
0344395604
-
Are we ready for pandemic influenza?
-
Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science 302:1519-1522
-
(2003)
Science
, vol.302
, pp. 1519-1522
-
-
Webby, R.J.1
Webster, R.G.2
-
169
-
-
0035857389
-
Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial
-
Welliver R, Monto AS, Carewicz O et al (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial. JAMA 285:748-754
-
(2001)
JAMA
, vol.285
, pp. 748-754
-
-
Welliver, R.1
Monto, A.S.2
Carewicz, O.3
-
170
-
-
67650217954
-
What is the optimal therapy for patients with H5N1 influenza?
-
White NJ, Webster RG, Govorkova EA et al (2009) What is the optimal therapy for patients with H5N1 influenza? PLoS Med 6:e1000091
-
(2009)
PLoS Med
, vol.6
-
-
White, N.J.1
Webster, R.G.2
Govorkova, E.A.3
-
172
-
-
0014671798
-
Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man
-
Wingfield WL, Pollack D, Grunert RR (1969) Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281:579-584
-
(1969)
N Engl J Med
, vol.281
, pp. 579-584
-
-
Wingfield, W.L.1
Pollack, D.2
Grunert, R.R.3
-
173
-
-
59749091876
-
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity
-
Yamashita M, Tomozawa T, Kakuta M et al (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186-192
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 186-192
-
-
Yamashita, M.1
Tomozawa, T.2
Kakuta, M.3
-
174
-
-
25844474747
-
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility
-
Yen HL, Herlocher LM, Hoffmann E et al (2005) Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-4084
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 4075-4084
-
-
Yen, H.L.1
Herlocher, L.M.2
Hoffmann, E.3
-
175
-
-
45849109558
-
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus
-
Zheng BJ, Chan KW, Lin YP et al (2008) Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 105:8091-8096
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 8091-8096
-
-
Zheng, B.J.1
Chan, K.W.2
Lin, Y.P.3
-
176
-
-
34948813121
-
Treatment with convalescent plasma for influenza A (H5N1) infection
-
Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357:1450-1451
-
(2007)
N Engl J Med
, vol.357
, pp. 1450-1451
-
-
Zhou, B.1
Zhong, N.2
Guan, Y.3
-
177
-
-
77952722772
-
Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel
-
Zonis Z, Engelhard D, Hindiyeh M et al (2010) Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis 16:1045-1046
-
(2010)
Emerg Infect Dis
, vol.16
, pp. 1045-1046
-
-
Zonis, Z.1
Engelhard, D.2
Hindiyeh, M.3
|